Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial-Reference-Cited by-同舟云学术

Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial

Published:2023-03 Issue: Volume:126 Page:107108
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Lim Jae-Sung,Lee Juneyoung,Kang Yeonwook,Park Hyun-Tae,Kim Dong-Eog,Cha Jae-Kwan,Park Tai Hwan,Heo Jae-Hyuk,Lee Kyung Bok,Park Jong-Moo,Oh Mi Sun,Kim Eung-Gyu,Chang Dae-Il,Heo Sung Hyuk,Park Man-Seok,Park HyunYoung,Yi SangHak,Lee Yeong Bae,Park Kwang-Yeol,Lee Soo Joo,Kim Jae Guk,Lee Jun,Cho Kyung-Hee,Rha Joung-Ho,Kim Yeong-In,Lee Jun Hong,Choi Jay Chol,Oh Kyung-Mi,Kwon Jee-Hyun,Kim Chulho,Park Jong-Ho,Jung Keun-Hwa,Sung Sang Min,Chung Jong-Won,Lee Yong-Seok,Kim Hahn Young,Cho Hyun-Ji,Park Jeong Wook,Moon Won-Jin,Bae Hee-Joon

Publisher

Elsevier BV

Subject

Pharmacology (medical),General Medicine

Reference47 articles.

1. Diagnosing vascular cognitive impairment: current challenges and future perspectives;Biesbroek;Int. J. Stroke,2022

2. Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review;Colucci;J. Exp. Pharmacol.,2012

3. Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia;Rozzini;Acta Neurol.,1992

4. Clinical studies with Oxiracetam in patients with dementia of Alzheimer type and multi-lnfarct dementia of mild to moderate degree;Villardita;Neuropsychobiology.,1992

5. (S)-Oxiracetam is the active ingredient in oxiracetam that alleviates the cognitive impairment induced by chronic cerebral hypoperfusion in rats;Li;Sci. Rep.,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuroprotective strategies for neonatal hypoxic-ischemic brain damage: Current status and challenges;European Journal of Pharmacology;2023-10

2. Health Provider’s Feedback on Physical Activity Surveillance Using Wearable Device-Smartphone Application for Adults with Metabolic Syndrome; a 12-Week Randomized Control Study;Diabetes, Metabolic Syndrome and Obesity;2023-05